Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Atherosclerosis (ATS)
3. Pathogenetic steps in atherosclerosis
4. Triggers and common pathway in atherosclerosis
5. Features of innate and adaptive immunity in ATS
6. Innate immunity factors involved in inflammatory
7. CRP distribution within the atherosclerotic plaque
8. CRP is a predictor of cardiovascular diseases
9. Unstable carotid plaque (CARS)
10. CD4+CD28null cells are expanded in angina
11. CD4+CD28null lymphocytes are pro inflammatory
12. CD4+CD28null in rheumatoid arthritis patients
13. CD4+CD28null cells and increased IMT
14. Atherosclerosis and autoimmunity
15. Role of oxLDL in foam cells formation
16. Anti-oxLDL and atherosclerosis
17. Protective and pathogenetic anti-oxLDL
18. Antiphospholipid antibodies
19. Structure of beta-2GPI
20. Surface charge and binding of beta-2GPI
21. Beta-2GPI as a target for APL Abs
22. Formation of oxLDL and beta-2GPI complex
23. oxLDL/beta-2GPI as an inflammation marker
24. The role of beta-2GPI in atherogenesis
25. beta-2GPI localization in atherosclerotic plaques
26. Immunization with beta-2GPI
27. Antiphospholipid antibodies in ATS patients
28. Example: protective role of anti-phospholipid Abs
29. Human heat-shock proteins (HSP)
30. Anti-heat shock protein (HSP) 60/65 antibodies
31. Enhanced ATS and associated factors in ARD
32. Atherosclerosis in RA - historical view
33. Coronary artery disease in RA patients
34. Coronary artery disease in SLE patients
35. Incidence of MI in SLE patients
36. Risk factors for atherosclerosis in SLE
37. Non-invasive techniques for detection of ATS
38. Duplex ultrasonography
39. Intima-media thickness (IMT) in RA patients
40. Risk factors for cardiovascular events
41. Parallelism between RA and atherosclerosis
42. Carotid ultrasound studies in SLE
43. Traditional and other metabolic risk factors for ATS
44. Cardiovascular risk in lupus
45. Novel risk factors for atherosclerosis
46. CRP and subclinical atherosclerosis in SLE
47. The relationship between autoantibodies and ATS
48. Subclinical atherosclerosis in SLE: study design
49. M-IMT and IgG anti-oxLDL levels - correlation
50. Mid conclusions
51. Questions which should be addressed
52. Correlates of accelerated atherosclerosis in SLE
53. Who are at highest risk for accelerated ATS?
54. Risk factors for carotid plaques in SLE
55. 78 SLE patients
56. PRD cumulative dosage in different patients
57. PRD dosage - adjusted for traditional risk factors
58. The bimodal mortality pattern of SLE
59. Long-term prognosis in SLE
60. Long-term prognosis in severe vs. mild SLE
61. Take home message
62. Conclusions
63. Role of the endothelium in vascular homoeostasis
64. Assessment of endothelial function
65. Ultrasonography of brachial artery
66. Endothelial dysfunction as predictor of CV events
67. Endothelial dysfunction in autoimmune diseases
68. Why does this correlation exist?
69. Distant effects of local vascular inflammation
70. Acknowledgments

Topics Covered

• Immunoinflammatory mechanisms involved in atherosclerosis
• Autoantibodies and atherosclerosis
• Clinical and subclinical atherosclerosis in rheumatoid arthritis
• Clinical and subclinical atherosclerosis in systemic lupus erythematosus
• Traditional and non-traditional risk factors for atherosclerosis in autoimmune rheumatic diseases
• Assessment of endothelial function in autoimmune rheumatic diseases
• Endothelial dysfunction in autoimmune rheumatic diseases

Links

Series:

• Autoimmunity

Categories:

• Clinical Practice
• Immunology

Therapeutic Areas:

• Immunology & Inflammation

Talk Citation

Doria, A. (2007, October 1). Accelerated atherosclerosis in autoimmune rheumatic disease [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved April 18, 2024, from https://hstalks.com/bs/199/.
Export Citation (RIS)

Publication History

• Published on October 1, 2007
• Archived on May 31, 2018

Financial Disclosures

• Dr. Andrea Doria has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.